Joshua Elkington is a founder-investor at Axial VC who brands the firm as an agency for great inventors, positioning himself as a long-term partner to individual inventors and founder-scientists rather than a traditional VC, with deep specialization in life sciences company formation. He operates at the intersection of life sciences and computer science, running the Axial Substack and Podcast where he publishes detailed strategy pieces on biotech business models and maintains close ties to the academic research community through his tracking of university labs and early-career scientists.

• Deep interest in advanced therapeutic modalities and the mechanisms behind them, specifically focusing on areas like directed evolution for antibody discovery, cell therapies for autoimmunity, and high-fidelity CRISPR. He frequently highlights specific innovators in the space, such as his coverage of BioLoomics and their work combining synthetic biology with machine learning to find new therapeutics.
• Focus on the intersection of software and biology, particularly how data analytics can solve complex infrastructure problems. A prime example is his enthusiasm for Invert, a company using software to manage the complex variables involved in biomanufacturing products like proteins and enzymes.
• Commentary on the economic realities and business models within the life sciences sector. He offers advice on how diagnostic or synthetic biology companies often feel market pressure to pivot into drug development to secure better financial returns, noting that drug development offers a clearer step-by-step playbook for creating massive value compared to other biotech verticals.
• Promotion of long-form intellectual conversations with technical founders through his content platform, Axial. He actively shares deep-dive interviews with industry leaders, such as his discussion with the CEO of Alloy Therapeutics about democratizing access to drug discovery platforms, suggesting he values founders who can articulate their scientific journey and technical nuance in detail.
• Strong support for the San Francisco tech ecosystem and in-person industry community building. He frequently posts about attending major industry gatherings like the J.P. Morgan Healthcare Conference and expresses a long-term bullish outlook on San Francisco as a hub for innovation.